User:Mr. Ibrahem/Fostemsavir

Mr. Ibrahem/Fostemsavir
Clinical data
Trade names	Rukobia
Synonyms	Fostemsavir tromethamine, BMS-663068, GSK3684934
AHFS/Drugs.com	Monograph
MedlinePlus	a620046
License data	EU EMA: by INN; US DailyMed: Fostemsavir;
Pregnancy; category	AU: B3; ;
Routes of; administration	By mouth
Drug class	HIV fusion inhibitor
Legal status
Legal status	AU: S4 (Prescription only) ; US: ℞-only ; EU: Rx-only ;
Identifiers
	IUPAC name {3-[(4-Benzoyl-1-piperazinyl)(oxo)acetyl]-4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl}methyl dihydrogen phosphate;
Chemical and physical data
Formula	C25H26N7O8P
Molar mass	583.50 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(c1ccccc1)N5CCN(C(=O)C(=O)c4c2c(c(ncc2OC)n3nc(nc3)C)n(c4)COP(=O)(O)O)CC5;
	InChI InChI=1S/C25H26N7O8P/c1-16-27-14-32(28-16)23-21-20(19(39-2)12-26-23)18(13-31(21)15-40-41(36,37)38)22(33)25(35)30-10-8-29(9-11-30)24(34)17-6-4-3-5-7-17/h3-7,12-14H,8-11,15H2,1-2H3,(H2,36,37,38); Key:SWMDAPWAQQTBOG-UHFFFAOYSA-N;

Fostemsavir, sold under the brand name Rukobia, is a medication used to treat HIV/AIDS.^[3] It is used together with other medications, when usually treatments are not effective.^[4] It is taken by mouth.^[4]

Common side effects include nausea, diarrhea, rash, and abdominal pain.^[4]^[3] Other side effects may include liver problems, QT prolongation, and immune reconstitution syndrome.^[4] It should not be taken with strong CYP3A inducers.^[3] It works by binding to the HIV virus and preventing it from entering T cells.^[3]

Fostemsavir was approved for medical use in the United States 2020, and Europe in 2021.^[2]^[3] In the United Kingdom a month of treatment costs the NHS £2,900 as of 2021.^[5] In the United States this amount costs about 8,000 USD.^[6]

References

↑ ^1.0 ^1.1 "Rukobia". Therapeutic Goods Administration (TGA). 23 July 2021. Archived from the original on 5 September 2021. Retrieved 5 September 2021.
↑ ^2.0 ^2.1 "Fostemsavir Monograph for Professionals". Drugs.com. Archived from the original on 21 January 2021. Retrieved 12 December 2021.
↑ ^3.0 ^3.1 ^3.2 ^3.3 ^3.4 ^3.5 ^3.6 ^3.7 "Rukobia EPAR". European Medicines Agency (EMA). 9 December 2020. Archived from the original on 12 February 2021. Retrieved 12 February 2021.
↑ ^4.0 ^4.1 ^4.2 ^4.3 ^4.4 ^4.5 ^4.6 "Rukobia- fostemsavir tromethamine tablet, film coated, extended release". DailyMed. 2 July 2020. Archived from the original on 15 July 2020. Retrieved 14 July 2020.
↑ "Rukobia · HIV infection". Retrieved 13 December 2021.{{cite web}}: CS1 maint: url-status (link)
↑ "Rukobia Prices, Coupons & Patient Assistance Programs". Drugs.com. Retrieved 13 December 2021.

[Rukobia_APM_summary-1] 1.0 ^1.1 "Rukobia". Therapeutic Goods Administration (TGA). 23 July 2021. Archived from the original on 5 September 2021. Retrieved 5 September 2021.

[AHFS2021-2] 2.0 ^2.1 "Fostemsavir Monograph for Professionals". Drugs.com. Archived from the original on 21 January 2021. Retrieved 12 December 2021.

[EPAR2021-3] 3.0 ^3.1 ^3.2 ^3.3 ^3.4 ^3.5 ^3.6 ^3.7 "Rukobia EPAR". European Medicines Agency (EMA). 9 December 2020. Archived from the original on 12 February 2021. Retrieved 12 February 2021.

[PI2021-4] 4.0 ^4.1 ^4.2 ^4.3 ^4.4 ^4.5 ^4.6 "Rukobia- fostemsavir tromethamine tablet, film coated, extended release". DailyMed. 2 July 2020. Archived from the original on 15 July 2020. Retrieved 14 July 2020.

[5] "Rukobia · HIV infection". Retrieved 13 December 2021.{{cite web}}: CS1 maint: url-status (link)

[6] "Rukobia Prices, Coupons & Patient Assistance Programs". Drugs.com. Retrieved 13 December 2021.

[1]

[2]

[4]

[3]

[5]

[6]